Table 3.
Use of an IDTB before therapy: stratified analysis
| Variable | Value | IDTB utilization, n (%) | No IDTB utilization, n (%) | Unknown |
|---|---|---|---|---|
| Year of diagnosis (n = 1,271) | Until 2013 | 104 (43.3) | 136 (46.7) | 155 |
| 2014–2015 | 86 (49.1) | 89 (50.9) | 36 | |
| 2016–2017 | 215 (61.8) | 133 (38.2) | 65 | |
| 2018–2019 | 151 (66.2) | 77 (33.8) | 24 | |
| Place of first treatment (n = 1,238) | In house − hospital/practice | 58 (65.2) | 31 (34.8) | 10 |
| In house − maximum care | 391 (72.8) | 146 (27.2) | 31 | |
| External − practice | 7 (19.4) | 29 (80.6) | 4 | |
| External − hospital | 55 (25.8) | 158 (74.2) | 116 | |
| External − university hospital/specialized center | 34 (44.7) | 42 (55.3) | 54 | |
| External − unknown place | 5 (18.5) | 22 (81.5) | 45 | |
| Patients treated in 2018 (n = 662)a | Up to 25 | 24 (61.5) | 15 (28.5) | 6 |
| 11–100 | 70 (88.6) | 9 (13.4) | 6 | |
| 101–500 | 192 (72.2) | 74 (27.8) | 13 | |
| More than 500 | 159 (67.1) | 78 (32.9) | 16 | |
| Comprehensive cancer center (n = 667)a | No | 108 (50.5) | 106 (49.5) | 13 |
| Yes | 341 (82.8) | 71 (17.2) | 28 | |
a
Data are available only for patients initially treated in participating centers.